Full-Time

National Corporate Account Director

Confirmed live in the last 24 hours

Corcept Therapeutics

Corcept Therapeutics

201-500 employees

Develops cortisol modulators for medical conditions

Biotechnology
Healthcare

Compensation Overview

$232.8k - $273.8kAnnually

Senior, Expert

Remote in USA

Applicants must be currently authorized to work in the United States on a full-time basis.

Category
Strategic Account Management
Sales & Account Management

You match the following Corcept Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Experience in oncology specialty distribution, specialty pharmacy, community oncology GPO, and community oncology key account management
  • Extensive customer relationships and experience
  • Experience launching oral oncology therapies in the community oncology setting with a focus on driving results and meeting or exceeding objectives
  • Demonstrated ability to meet assigned objectives and drive results within agreed upon timelines
  • Effective oral and written communication skills and ability to engage at all levels of the organization including C-Suite level relationships
  • Excellent negotiation skills with a focus on finding solutions to meet organizational goals
  • Collaborative work and communication style fostering cross-functional teamwork
  • Working knowledge of US healthcare policies and relevant legal, compliance, regulatory, and reporting requirements
Responsibilities
  • Execute the specialty distribution, community GPO, and key account strategies to ensure appropriate practice adoption and patient access
  • Negotiate specialty distribution (SDs) service agreements and related agreements, and maintain agreed upon service levels. Perform periodic business reviews
  • Negotiate service and data-sharing agreements with assigned oncology Specialty Pharmacy partners to meet brand objectives
  • Coordinate periodic business reviews
  • Identify and manage the execution of educational opportunities with assigned community oncology GPOs (ie Unity, Onmark, ION, etc.) to inform GPO members and support patient access through GPO meeting sponsorships opportunities and in-practice programs
  • Negotiate and manage GPO contracts to support patient access through in-practice dispensing
  • Manage relationships with community oncology key accounts with in-practice dispensing capabilities and centralized decision making
  • Collaborate with the field sales team to ensure coordination in key community oncology accounts
  • Support partnerships with assigned oncology trade organizations such as COA and NCODA
  • Analyze product volume, trends, and growth, for assigned accounts. Develop and implement account level business plans and work with market access marketing to develop segment strategies and resources
  • Monitor and ensure that partners adhere to contract terms
Desired Qualifications
  • Bachelor’s Degree; Master’s degree preferred
  • Strategic mindset and patient-centric approach to the business
  • Ability to thrive in a fast-paced, dynamic environment
  • 10+ years of pharmaceutical industry experience including current and/or previous oncology experience
  • 5+ years of related assigned account experience
  • Pharmaceutical field sales leadership experience preferred

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by excessive cortisol. Korlym was the first drug approved by the FDA for this condition in 2012. Corcept stands out from competitors by having discovered over 1,000 selective cortisol modulators and by heavily investing in research and development to create new treatments. The company's goal is to expand its product offerings while also providing educational resources to improve patient care and understanding of cortisol-related disorders.

Company Size

201-500

Company Stage

IPO

Total Funding

$39.7M

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.
  • Advancements in drug delivery systems could enhance Corcept's product efficacy.
  • The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

What critics are saying

  • Teva's antitrust lawsuit could lead to legal expenses and market share loss.
  • Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.
  • Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few direct competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.
  • Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

2%

2 year growth

-3%
Investing.com
Dec 30th, 2024
Corcept files NDA for new Cushing's syndrome drug

Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.

MarketBeat
Oct 8th, 2024
Algert Global LLC Invests $412,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Algert Global LLC invests $412,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Defense World
Sep 29th, 2024
Evergreen Capital Management LLC Invests $217,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Evergreen Capital Management LLC invests $217,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Defense World
Aug 16th, 2024
Cetera Advisors LLC Makes New Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT)

Cetera Advisors LLC makes new investment in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Investing.com
Jun 29th, 2024
Teva study questions treatment breaks for migraine prevention

Teva has also initiated an antitrust lawsuit against Corcept Therapeutics (NASDAQ:CORT), alleging a monopoly over the Korlym market, a treatment for Cushing's syndrome.